AstraZeneca AZN announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) rendered ...

BeiGene's Tevimbra gets a highly sought after recommendation.

Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion recommending approval for the Blenrep ...

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced that the Committee for Medicinal Products for Human ...

RHHBY's Itovebi combo wins CHMP backing for PIK3CA-mutated breast cancer, showing strong survival benefits in phase III ...

NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Autolus Therapeutics' autologous CD19-directed CAR T-cell therapy Aucatzyl ...

EU regulators have recommended AstraZeneca’s Imfinzi for approval in the treatment muscle-invasive bladder cancer (MIBC).

EMA committee recommends marketing approval for SpringWorks’ mirdametinib to treat adult & paediatric patients with NF1-PN: Stamford, Connecticut Tuesday, May 27, 2025, 12:00 Hr ...

The antibiotic can no longer be used in moderate acne vulgaris, eradication of Helicobacter pylori, and prevention of ...

GSK plc (NYSE:GSK) has strengthened its market outlook following major regulatory milestones. The U.S. FDA’s recent approval ...

The new infusion for maple syrup urine disease is for patients who cannot have an oral or enteral branched-chain amino ...

EMA committee recommends approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer: Basel Monday, May 26, 2025, 12:00 Hrs [IST] Roche an ...